DALLAS, July 22, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/VVUS
VVUS's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, VVUS is trading below its lower Bollinger Band. Relative to recent price action, the stock is currently overextended to the downside and due for either a pause or retracement.
VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company's product pipeline includes three late-stage clinical products. One of these investigational products, Qnexa, is in phase 3 clinical trials for obesity and in phase 2 clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which two of the phase 3 studies are in process and one phase 3 study has been completed; Qnexa for treating diabetes, for which a one-year phase 2 study has been completed; Avanafil, which is being developed for the treatment of erectile dysfunction, for which phase 3 studies are in process; and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a phase 2 study has been completed.
Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS
In the report, the analyst notes:
"Product revenues from the sale of MUSE in the first quarter of 2010 were $1.6 million as compared to $1.2 million in the first quarter of 2009 due to the increase in number of units sold in 2010 as compared to last year. Total revenue for the first quarter of 2010 was $1.7 million as compared to $22.2 million for the first quarter of 2009.
"VVUS currently has five late stage clinical development programs in progress that target obesity, diabetes, sleep apnea, and sexual health. Current research suggests that there is significant unmet need among patients living with these conditions."
To read the entire report visit: http://www.microstockprofit.com/lp/VVUS
See what investors are saying about VVUS at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.